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The macrolide class of antibiotics, including the early generation macrolides erythromycin, clar-
ithromycin and azithromycin, have been used broadly for treatment of respiratory tract infections. An
increase of treatment failures of early generation macrolides is due to the upturn in bacterial macrolide
resistance to 48% in the US and over 80% in Asian countries and has led to the use of alternate therapies,
such as fluoroquinolones. The safety of the fluoroquinolones is now in question and alternate antibiotics
for the outpatient treatment of community acquired bacterial pneumonia are needed. Telithromycin,
approved in 2003, is no longer used owing to serious adverse events, collectively called the ‘Ketek effects’.
Telithromycin has a side chain pyridine moiety that blocks nicotinic acetylcholine receptors. Blockade of
these receptors is known experimentally to cause the side effects seen with telithromycin in patients use.
Solithromycin is a new macrolide, the first fluoroketolide, which has been tested successfully in two
Phase 3 trials and is undergoing regulatory review at the FDA. Solithromycin is differentiated from teli-
thromycin chemically and biologically in that its side chain is chemically different and does not signifi-
cantly block nicotinic acetylcholine receptors. Solithromycin was well tolerated and effective in clinical
trials.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Macrolide antibiotics have been used successfully to treat respi-
ratory tract and other bacterial infections. This success is due in
large part to their (i) spectrum of activity, (ii) safety, (iii) tissue
and intracellular activity, and (iv) anti-inflammatory properties.
These properties give macrolides an advantage over other classes
of antibiotics. Their spectrum of activity in the respiratory tract
is targeted to key community-acquired pathogens including Strep-
tococcus pneumoniae, Haemophilus influenzae, Staphylococcus aur-
eus, and atypical pathogens such as Legionella pneumophila,
Mycoplasma pneumoniae and Chlamydophila pneumoniae. The atyp-
ical bacteria do not have peptidoglycan in their cell wall and there-
fore infection caused by these organism cannot be treated with
penicillin or other beta-lactam antibiotics, leaving tetracyclines,
fluoroquinolones and macrolides as the only single-agent oral
treatment options. Although broad spectrum antibiotics such as
cephalosporins, aminopenicillins, tetracyclines, and fluoro-
quinolones are active against typical community-acquired bacte-
rial pneumonia (CABP) pathogens, their extended spectrum of
activity can cause collateral damage by modifying intestinal micro-
flora. Notably, fluoroquinolones such as levofloxacin and moxi-floxacin are known to cause Clostridium difficile colitis by altering
intestinal microbiome. Further, tetracyclines and fluoroquinolones
are not used in pediatrics to treat respiratory tract infections
because of undesirable side effects. In contrast, macrolides have
been generally safe and well tolerated in adults, children, and preg-
nant women. As a result, a macrolide is frequently the ‘go to’
antibiotic for empiric treatment of respiratory tract infections.
Many bacteria reside, and replicate intracellularly in phagolyso-
somes and cytoplasm. Macrolides also concentrate in alveolar
macrophages, extracellular lung fluid (ELF), and some organ tissues
such as the lung. Therefore, high concentrations of macrolides can
be achieved where needed, including intracellular environments.
Lastly, macrolides exhibit a positive immunomodulatory, anti-
inflammatory response, likely due to inhibition of cytokine release
from inflammatory cells and decreased tissue damage which is
considered to provide a clinical benefit and enhancement of clini-
cal efficacy.
2. The need
Since the introduction of the first macrolide, erythromycin in
1957, and the semi-synthetic analogs clarithromycin and azithro-
mycin in the late 1980’s, widespread macrolide usage has resulted
in increased microbial resistance with resistance rates at an
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other classes of antibiotics, is higher in Asia.2 No doubt, the overuse
of antibiotics in simple upper respiratory tract infections, like
sinusitis and bronchitis, and veterinary use for livestock has
enhanced the selection for resistance. Simple upper respiratory
tract infections are not life threatening; in fact are often due to
viral pathogens. Empiric, often indiscriminate antibiotic use
increases selection of resistant bacteria. Recognizing this, there is
a renewed effort in healthcare to discourage antibiotic use for sim-
ple, uncomplicated sinusitis, bronchitis, and other uncomplicated
upper respiratory infections.3–5 Macrolide treatment failure of
CABP, a leading cause of hospitalization and death among adults
in the U.S,6 is possibly the result of infection by macrolide-resistant
bacteria.7 Over the past several years, use of fluoroquinolones to
treat CABP has steadily increased to cover macrolide-resistant
pathogens, including pneumococci.8 Antibiotic-resistant M. pneu-
moniae has also increased9–12 but exact rates are unknown since
this bacterium is difficult to culture and susceptibility testing is
done only in specialized laboratories.
The 2007 Infectious Diseases Society and the American Thoracic
Society (IDSA/ATS) guidelines for the treatment of CABP recom-
mends treatment with a fluoroquinolone or a beta-lactam plus a
macrolide.13 However, fluoroquinolones such as levofloxacin has
several downsides including alteration of the intestinal microflora
resulting in C. difficile colitis, tendonitis, neuritis, and hallucina-
tions.16 Outpatient treatment failures have increased in recent
years leading to an increase in hospitalizations.14,15 Although still
indicated for the treatment of CABP, the mounting weight of
adverse events prompted the FDA to re-examine the benefit/risk
resulting in an update to the US labeling and medication guides
for all fluoroquinolones.16 Fluoroquinolones are potent and useful
antibiotics, but should be preserved for use in hospitalized criti-
cally ill patients where they may be life-saving. Current alterna-
tives to fluoroquinolones for the treatment of hospitalized CABP
patients are combination of a beta-lactam antibiotic plus a macro-
lide or tetracycline, a treatment regimen supported by studies that
showed reduced mortality among patients who received combina-
tion antibiotic therapy for bacteremic pneumococcal pneumonia.17
The improved clinical response in CABP patients administered a
macrolide together with a third generation cephalosporin18 versus
a broad spectrum cephalosporin alone has been reported.19 As an
alternative for empiric therapy, a macrolide or tetracycline pro-
vides coverage for atypical bacteria. Unfortunately, since all of
the third generation cephalosporins are injectable, with no oral
alternative, patients cannot be discharged early from the hospital
to continue treatment with an oral third generation cephalosporin.
In summary, it is still possible to treat CABP, but with increasing
bacterial resistance to oral antibiotics typically used for outpa-
tients, current treatment options are all sub-optimal, requiring
hospitalization and/or compromising safety or efficacy.
3. Overcoming macrolide resistance with the ketolides
In recent years, nearly one out of two (50%) strains of pneumo-
coccus in the U.S. is now resistant to macrolides.1 Such resistance
has led to a substantial increase in both hospitalizations and
healthcare costs.20 The second generation macrolides, clar-
ithromycin and azithromycin, have chemical modifications in the
macrocyclic ring (shown in Fig. 1) that improved bioavailability
and pharmacokinetics over that of the first generation macrolide
erythromycin but do not confer activity against erythromycin-
resistant strains.
All macrolides exert their activity by interacting with the bacte-
rial ribosome, thereby disrupting protein synthesis. Since both
macrolide generations share the same single ribosomal bindingsite at A2058/A2059 (Escherichia coli numbering) of the 23S RNA
of the 50S ribosomal subunit, they have similar potencies and are
cross-resistant. Telithromycin is a third generation macrolide with
activity against pneumococci resistant to the first and second gen-
eration macrolides (shown in Fig. 2).
Telithromycin has a keto group at position 3 of the macrocyclic
ring (numbered on the figure) instead of the cladinose sugar of the
older macrolides and a side chain at the 11,12 position that inter-
acts with domain II, at A752, of the 23S RNA.21 This second binding
site of telithromycin confers activity against macrolide-resistant
strains.22 It binds to the bacterial ribosome with high affinity and
is bactericidal23 while older macrolides are considered bacterio-
static. It is noteworthy that these modifications led to an unusual
change in antibacterial development; namely a change in the
mode-of action from bacteriostatic to bactericidal within the same
class of antibiotic. This feature is clinically relevant since earlier
generations of macrolides were considered for use in serious infec-
tions caused by pathogens, such as pneumococci only when co-
administered with another antibiotic capable of rapid bactericidal
activity. Telithromycin received marketing authorization for a
number of simple respiratory tract infections as well as CABP by
the U.S. Food and Drug Administration in 200424 and was marketed
under the brand name Ketek. In late 2006, after reports of various
adverse events collectively called the ‘Ketek effects’, (adverse
events that included reversible visual accommodation effects, most
frequently noted in young women, syncope, exacerbation of myas-
thenia gravis, and rarely but most widely reported idiosyncratic
hepatic effects that were serious enough to lead to hepatic failure
in a select number of patients)25 were discussed at a widely publi-
cized FDA advisory committee meeting. The liver toxicity observed
with telithromycin was unusual in that it involved eosinophilic
infiltration and inflammatory response that rapidly led to necrotic
cell death.26,27 The marketing indication for CABP was retained, but
indications for use in simple infections like sinusitis, pharyngitis,
bronchitis, etc., and skin infections were removed from the label.27
Telithromycin is no longer actively marketed.
Most antibiotics, including macrolides, can cause reversible
liver enzyme elevations because of the large dose of drug adminis-
tered to patients.28 Antibiotic doses are in the range of 250–
1000 mg per dose relative to the 1–20 mg doses generally used
in the treatment of central nervous system and cardiac diseases.
After the large amount of negative publicity surrounding Ketek,
changes were instituted by the FDA for antibiotic approval. New
guidelines which excluded upper respiratory tract infections that
could be self-limited or of a viral etiology were developed to
encourage the development of antibiotics for serious infections,
such as CABP.29 These new guidelines encourage stewardship of
new antibiotics to decrease the possibility of resistance selection
by limiting use in simpler upper respiratory tract infections with
the aim of extending the clinical useful period of new antibiotics.
Many, if not all, large pharmaceutical companies had invested
in macrolide and ketolide research into the early 2000s. These
efforts led to macrolide/ketolide compounds that were as potent
as or better than telithromycin. Some of these compounds are
described in a recent review.30 One compound, cethromycin, was
out-licensed by Abbott Labs (Chicago, IL) and developed by a
start-up company, Advanced Life-Sciences.31 Cethromycin was a
ketolide like telithromycin, but the location of the side chain is at
the 6 position (shown in Fig. 3).
Although microbial activity was similar to telithromycin,
cethromycin was highly protein bound and was a CYP3A4 inducer,
which led to poor oral bioavailability. Larger doses of cethromycin
could not be used as they resulted in unacceptable increased gas-
trointestinal motility. Although no safety concerns were revealed
in the Phase 3 trials, cethromycin was not non-inferior to
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Figure 1. Chemical structures of first generation (erythromycin) and second generation (clarithromycin and azithromycin) macrolide antibiotics.
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Figure 2. Chemical structure of telithromycin.
6422 P. Fernandes et al. / Bioorg. Med. Chem. 24 (2016) 6420–6428clarithromycin in the sicker CABP patient (possibly due to poor
bioavailability). A New Drug Application (NDA) submitted in
2008 failed to gain approval by FDA.32
The mechanism behind the Ketek adverse events were
unknown and differentiation of other macrolide/ketolide com-
pounds from Ketek could not be determined pre-clinically. As a
result, no other macrolide/ketolide reached late clinical develop-
ment and all programs were terminated.Figure 3. Chemical structure of cethromycin.4. Development of a new, effective and a well tolerated
macrolide
In 2003–2005, at the time when a large number of pharmaceu-
tical companies were trying to discover a lead macrolide that
would be competitive with telithromycin, Optimer Pharmaceuti-
cals in San Diego made and tested hundreds of macrolides and
ketolides. Working with scientists from the Scripps Institute, they
used copper click chemistry to synthesize a novel 5-membered
1,2,3-triazole ring which was incorporated into the side chain of
the 11–12 carbamate at the position of the imidazole in the side
chain of telithromycin. Control of the stereo chemical substitution
on the 1,2,3-triazole ring via copper(I) catalysis had never been
accomplished before the discovery by Professor Sharpless33 as well
as by Tornoe.34 Unlike imidazoles that are metabolically unstable
in vivo, the 1,2,3-triazole ring has the advantage of being metabol-
ically stable. Cempra Pharmaceuticals was founded by in-licensing
the entire macrolide program from Optimer Pharmaceuticals with
the hope of finding a suitable lead candidate to develop. Among the
several hundred molecules made at Optimer, one, which was
coded OP-1068, showed the best activity both in vitro and in ani-
mal infection models. After licensing the macrolide program, dis-
cussion at Cempra focused on three lead molecules; OP-1068,
OP-1055, the des-2-fluorine analog of OP-1068, and a third mole-
cule that had only a phenyl group at the terminus of the side chain
instead of the aminophenyl group of OP-1068 (shown in Fig. 4).
We noted that OP-1068, recoded CEM-101 and later named
solithromycin by Cempra, was the most potent in vitro and the
only one of the three molecules that had activity against telithro-
mycin-resistant bacterial strains. In addition to activity against tel-
ithromycin-resistant strains, it was predicted to be chemically
stable owing to the 1,2,3-triazole and the 2F.
Testing many analogs with and without the 2-F revealed that
there was complementarity in the ribosome interactions between
the 2-F and the aminophenyl in the side chain. The binding of soli-
thromycin to bacterial ribosomes with multiple and strong interac-
tions has been confirmed by X-ray crystallography studies (shown
in Fig. 5).35
The aminophenyl as well as the 1,2,3, triazole provided multiple
ribosomal interactions for solithromycin that were not observed in
the telithromycin–ribosome complex. The desosamine sugar of
solithromycin interacted with the ribosome in the same manner
as all macrolides. The 2-Fluorine of solithromycin also has an inter-
action with the ribosome resulting in a third interaction site and is
believed to contribute to improved pharmacokinetics. In addition
to enhancing its activity against telithromycin-resistant strains
and pharmacokinetics, the 2-F prevents the 3-keto from enoliza-
tion previously observed with telithromycin and other ketolides
as noted in solution by nuclear magnetic resonance (NMR) (as
shown in Fig. 6).36
Figure 5. Crystallographic structure of solithromycin bound to the E. coli ribosome at 3.2 Å. (A) Solithromycin (pink) and telithromycin (yellow) positions of the macro-
lactone ring and the alkyl aryl side chain in interactions with the ribosome; (B) Solithromycin alkyl aryl side chains interactions with the ribosome; (C) Solithromycin and
telithromycin interactions with the ribosome; (D) Proximity of solithromycin’s fluorine to base pair C2611-G2057 of the ribosome (Antimicrobial Agents and Chemotherapy,
2010, 54(12), 4965 (only Fig. 5 part D is reproduced), doi: http://dx.doi.org/10.1128/AAC.00860-10, reproduced with permission from American Society for Microbiology.
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6424 P. Fernandes et al. / Bioorg. Med. Chem. 24 (2016) 6420–6428Thus, solithromycin is the first ‘pure’ ketolide. The importance
of the 2-F addition, which enhanced the activity against telithro-
mycin-resistant strains, was recognized by naming solithromycin
as a fourth generation macrolide and the first fluoroketolide.
Since reservation was expressed by expert advisors on develop-
ing a drug that had an aniline moiety (aminophenyl), extensive
metabolic stability experiments were conducted on solithromycin
to determine if the aminophenyl would be metabolized to reactive
metabolites or be cleaved to release aniline. Even with very sensi-
tive detection methods, down to 1.0 nM, no aniline was detected
after metabolism by hepatocytes. These studies provided reassur-
ance to concerns about aniline or aminophenyl related toxicities
recognized in other marketed medications such as sulfamethoxa-
zole, sulfanilamide, and para-aminosalicylic acid. Cempra then
conducted three in vitro genetic toxicology assays; bacterial
reverse mutation assay (the Ames test) with and without S9 activa-
tion, mouse lymphoma forward mutation assay and chromosomal
aberration in human peripheral blood lymphocytes assay that are
used to show that a drug is not mutagenic in vitro. In addition, soli-
thromycin was also tested in the in vivo rat bone marrowmicronu-
cleus assay. Solithromycin was not mutagenic or clastogenic in any
of these studies. As a result, the aminophenyl was no longer con-
sidered to have any aniline-associated side effects of mutagenicity
or toxicity.
Solithromycin was well tolerated in one-, and three-month oral
toxicology studies conducted in rats and monkeys. In the 3-month
toxicology studies, with doses up to 125 mg/kg administered once
per day, all animals survived and during the 3 month recovery per-
iod after completion of dosing most tissue and organ changes
noted during dosing resolved. Following these studies, clinical
Phase 1 single and multiple dose escalation studies commenced.37
Pharmacokinetics data from these studies were used in pharma-
cokinetics and pharmacodynamics (PK/PD) assessments to select
for the Phase 2 study in CABP patients a dosing regimen of a single
800 mg oral loading dose on day 1 followed by a single dose of
400 mg (maintenance dose) on the following four days.
The Phase 2 trial, which was a double blind, multicenter study
in moderate to moderately severe CABP, was conducted as a two
arm 1:1 randomization study using 750 mg levofloxacin as the
comparator. Since monotherapy was going to be tested in moder-
ate to moderately severe CABP patients, azithromycin was consid-
ered inappropriate since pneumococcal azithromycin resistance
had risen to over 30% as early as 2012. In this Phase 2 trial, the first
time that a macrolide was tested as monotherapy in moderate to
moderately severe CABP, solithromycin had an acceptable safety
profile and was statistically non-inferior to levofloxacin.38
5. Telithromycin’s pyridine—The smoking gun
In 2012 when Cempra completed Phase 2 development, many
experts stated that telithromycin also had not shown adverse
events in clinical development. However, a review of the telithro-
mycin clinical literature, revealed that in published telithromycin
trials, as early as Phase 1, subjects reported visual effects at high
doses (although other major adverse events that were later noted
were not observed).24 We examined the structure of telithromycin
for clues that could explain the reported serious adverse events.
Telithromycin contains a pyridine ring at the terminus of the side
chain as illustrated in Figure 7.
Pyridine moieties are generally employed by medicinal che-
mists working in the CNS area to obtain activity against nicotinic
acetylcholine receptors (nAChRs).39,40 Extensive experiments con-
ducted by Dr. Daniel Bertrand, an expert in nicotinic acetylcholine
receptors (nAChRs), and his staff tested telithromycin, solithromy-
cin, and the older macrolides against human nAChRs expressed inXenopus oocytes.41 These experiments demonstrated that telithro-
mycin blocked the nAChRs found in the ciliary ganglion of the eye,
in particular the a7 and a3b4 receptors. These receptors are
involved in visual accommodation; blockade of these receptors
causes reversible visual disturbance. The finding that young
women were more often than men to have visual disturbances
after treatment with telithromycin could be explained by proges-
terone sensitization of these receptors.42 These data offer a mech-
anistic explanation for blurry vision due to interference of visual
accommodation. The possible reason for syncope was proposed
to be caused by inhibition of the a3b4 nAChRs with decreased
vagal activity caused by the pyridine-containing piece of the teli-
thromycin side chain cleaved at the imidazole. In order to explain
the adverse event finding of myasthenia gravis, the nAChRs at the
neuromuscular junction were examined. The a3b2 pre-synaptic
nAChR and the post neuromuscular junction abde receptors were
shown to be antagonized by telithromycin, thereby explaining
the exacerbation of myasthenia gravis seen in some patients trea-
ted with telithromycin. We next thought about the cause for teli-
thromycin-associated hepatic toxicity.
Branches of the vagus nerve terminating in the liver and hepatic
macrophages express a7 nAChRs. These receptors are identical to
the a7 nAChRs in the ciliary ganglion in the eye. Tracey et al. has
demonstrated that when stimulated, hepatic a7 nAChRs block
cytokines, like TNFa release by the cholinergic cytokine path-
way.43,44 Thus, the a7 nAChRs have a protective function in the
liver. Activation of a7 nAChRs blocks liver injury from an acute
inflammatory response while blockade promotes a cytokine rush,
potentially causing liver injury and apoptosis. Telithromycin
blocks the cholinergic anti-inflammatory response, allowing
macrophages to release a number of cytokines, including TNFa.
Thus, a patient who is predisposed to liver inflammation, for exam-
ple from alcohol or acetaminophen, might develop centrilobular
necrosis and eosinophilic infiltration, also seen in patients with
hepatic failure, and is strongly suggestive of acute liver injury
related to hypersensitivity.26,27 In the rat model, direct electrical
stimulation of the vagus nerve in vivo during endotoxemia inhib-
ited TNF synthesis in the liver, and prevented development of
shock.44,45 In other animal models, loss of vagal regulation of hep-
atic inflammation (by vagotomy) has been demonstrated to
increase the lethality of pro-inflammatory insults to the liver.43,46
Through its inhibition of nAChRs, telithromycin may dampen feed-
back inhibition of systemic inflammation, perhaps explaining the
unique hepatotoxicity of that molecule in comparison with the
older macrolides.
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by telithromycin-related inhibition of nAChRs (shown in Fig. 8).
Unlike telithromycin, the aryl–alkyl side chain of solithromycin
does not have a pyridine moiety, does not significantly block a7
nAChRs, and thus is chemically and biologically differentiated from
telithromycin (shown in Fig. 9).
6. Intravenous dosing formulation for solithromycin
In addition to the oral formulation used in previous trials, a soli-
thromycin intravenous formulation was developed to allow dosing
of hospitalized patients with CABP or seriously ill patients with
CABP requiring 1–2 doses of an antibiotic administered in the
emergency room. Solithromycin intravenous toxicology studies
for up to 28 days showed that daily solithromycin administration
was well tolerated in both dogs and monkeys. Unlike all the older
macrolides, solithromycin did not prolong the QT interval which
allowed safe administration of large intravenous doses without
risk of causing arrhythmias.47 Although an intravenous formula-
tion of telithromycin had been made, Phase 3 trials with a telithro-
mycin IV infusion formulation were not published.48 Solithromycin
was shown to be safe and well tolerated in a Phase 1 safety trialFigure 8. Nicotinic acetylcholine receptors and their distribution in various organs. Nicot
brain. (A) Variety of nACh receptors; (B) nACh receptors in the ciliary ganglion of the ey
response via the a7 nACh receptor at the vagus nerve and macrophages in the liver w
Inhibition of these a7 nACh receptors and this autonomic response results in FAS activ
receptors at the vagus nerve nucleus at the base of the brain, wherein the subsequent bwhich allowed Cempra to eventually conduct a Phase 3 IV to oral
CABP trial.49
7. Phase 3 clinical trials
The solithromycin oral and intravenous formulations have been
tested in two global Phase 3 trials which demonstrated that oral
and IV solithromycin is well tolerated and non-inferior to moxi-
floxacin, a potent, broad spectrum fluoroquinolone.49,50 Two New
Drug Applications (one for oral solithromycin and one for IV soli-
thromycin) for the use of solithromycin in the treatment of moder-
ate to moderately-severe CABP have been submitted to the FDA.
Solithromycin has received Priority Review and Fast Track designa-
tion from the FDA and, if approved, Cempra plans to market the
antibiotic in the U.S.
8. Solithromycin in pediatrics
New drugs need to be developed for use in children. To this end,
two U.S. laws have been enacted. The first is the Pediatric Research
Equity Act (PREA), which requires pharmaceutical companies to
study the drug product in children for the same indication forine binds and activates nicotinic acetylcholine receptors in the eye, muscle, liver and
e; (C) nACh receptors at the neuromuscular junction; (D) The brain and autonomic
hose function is to inhibit damaging cytokine release, such as TNF-a in the liver.
ation and apoptotic cell death in the liver. The brain also contains the a3b4 nACh
locking of its signal could result in syncope.
Figure 9. Chemical differentiation of solithromycin from telithromycin.
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ticals for Children Act (BPCA), which provides the pharmaceutical
company with an additional six months of marketing exclusivity
as an incentive to conduct FDA-requested pediatric studies. Prior
to these laws, most drugs approved for adult use in the US were
used ‘‘‘off-label’ in children without demonstration of safety, effec-
tiveness or appropriate pharmacokinetics in children. Children,
especially newborns to 8 years, metabolize and eliminate drugs
quite differently than adults, and hence the pharmacokinetics
can be drastically different. In the last decade only new antibiotics
with IV formulations, such as ceftaroline, have been tested in chil-
dren with CABP. Since oral formulations of these antibiotics are not
available, pediatricians do not have convenient oral formulations
to prescribe, and so they must resort to injectable antibiotics
requiring hospitalization for children with CABP. Although there
are oral tetracycline and fluoroquinolone formulations, these are
not recommended for use in children because of safety, leaving
amoxicillin and amoxicillin/clavulanic acid as the only oral treat-
ment alternatives for CABP in children. While these antibiotics
are effective against pneumococcus and many H. influenzae, they
have no activity against Mycoplasma, leaving a treatment gap for
children.51,52
Historically, macrolides were commonly used to treat CABP and
other respiratory infections in pediatrics. The safety, efficacy and
targeted spectrum of activity of macrolides have been useful in
treating respiratory tract infections in children, but in recent times
have lost their utility because of increasing resistance. The safety
and tolerability of solithromycin in adult CABP studies led to fund-
ing from The Biomedical Advanced Research and Development
Authority (BARDA) to support the development of oral capsules,
oral suspension, and IV solithromycin formulations, as well as clin-
ical studies in pediatric age groups for newborns to children
17 years of age. Initial safety and pharmacokinetic data on the oral
and intravenous formulations have been reported in some of the
age groups.53,54 A pivotal Phase 2/3 trial in children with CABP
(from neonates to age 17) has been initiated with oral capsules,
oral suspension and intravenous formulations.
9. Additional indications
Neisseria gonorrhoeae has become resistant to all oral antibi-
otics. The current recommended treatment is intramuscular ceftri-
axone and 1000 mg of azithromycin orally (the latter to treat
Chlamydia, which is frequently a co-infection).55 A single dose of
oral solithromycin was shown to be clinically effective and micro-
biologically active against N. gonorrhoeae in a Phase 2 study ofpatients with uncomplicated gonorrhea with or without chlamydia
infection.56 Due to this unmet need, a single, oral 1000 mg dose of
solithromycin is being evaluated in a Phase 3 trial to treat gonor-
rhea with or without concomitant chlamydia infection.
Solithromycin did not show untoward effects in Segment I,
Segment II and Segment III reproductive and developmental toxi-
cology studies, which will facilitate an evaluation of solithromycin
use during pregnancy. In Australia, studies in pregnant ewes, a sur-
rogate model for human pregnancy, demonstrated solithromycin
achieved potentially useful concentrations in amniotic fluid, cord
blood and placenta.57,58 In an ex vivo placental perfusion model,
solithromycin was efficiently transferred across the human pla-
centa.59 These features, coupled with the potent activity against
Group B Streptococcus,60 Ureaplasma,61,62 Mycoplasma hominis63
and Gardnerella vaginalis64 could make it a very useful antibiotic
for this special population.
The anti-inflammatory benefit from macrolides has led to
chronic administration to patients with Chronic Obstructive Pul-
monary Disease (COPD) and cystic fibrosis.65,66 The anti-inflamma-
tory effects are proposed to be through the upregulation of HDAC-2
promoter (histone deacetylase-2) which results in a subsequent
downregulation of important cytokines, such as TNFa.65,67 In vitro,
studies, including those with macrophages from COPD patients
demonstrate that solithromycin is also capable of modulating the
immune response, perhaps to a greater extent than the older
macrolides.68 It was also more active than the older macrolides
in a mouse model for COPD, where mice were exposed to cigarette
smoke to induce pulmonary disease reminiscent of COPD.65 Since
solithromycin does not enter the mammalian nucleus (unpub-
lished observations, P. Tulkens, Université Catholique de Louvain),
the mechanism of HDAC-2 promoter activation could be indirectly
through inhibition of Akt phosphorylation.67 The particular target
in the pathway for Akt phosphorylation inhibition has not yet been
identified but has been shown not to be through the inhibition of
PI3K enzymes.67 Further studies are expected to determine if soli-
thromycin could provide benefit to COPD patients.
10. Conclusions
There is an increasing need for a new macrolide as a result of
increasing resistance associated with older antibiotics as well as
safety issues associated with fluoroquinolones. Based on the chem-
ical structure, safety and tolerability of solithromycin was antici-
pated, and then confirmed by pre-clinical and clinical studies.
The side chain and the 2-fluorine of solithromycin imparts potency
to the macrolide pharmacophore. If solithromycin receives
P. Fernandes et al. / Bioorg. Med. Chem. 24 (2016) 6420–6428 6427marketing approval, intravenous and oral formulations are
expected to provide flexibility in dosing CABP patients, and allow
patients to be switched from IV to oral drug. Treatment with soli-
thromycin in the outpatient may allow for a complete hospitaliza-
tion avoidance or reduce the patient’s length of stay. Development
of a pediatric suspension for treating children unable to swallow
oral capsules, and an intravenous formulation will provide dosing
flexibility to pediatricians and their patients. Assuming solithro-
mycin obtains marketing approval, the shadow of Ketek will be left
behind, to bring a much needed antibiotic to the market.
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